

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

28 Jun 2026

### Effect of curcumin on liver function enzymes in patients with NAFLD

#### Protocol summary

##### Summary

The effect of curcumin on inflammatory factors: lipid profile: glycemic index: anthropometric indices: sonographic finding and liver function in patients with NAFLD. Inclusion criteria: not suffering from diseases such as cardiovascular problems: kidney: lung: thyroid disorders: non-smoking and inflammatory drugs like celecoxib. Exclusion criteria: patients with diseases such as cardiovascular problems: kidney: lung: thyroid disorders: Are pregnant: smoking and drugs like celecoxib inflammation: Patients with non-alcoholic fatty liver: alcoholic: a sample size of 80 intervention trial period 09/15/93 to 11/15/93 outcome: treatment

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2014110511763N18**  
Registration date: **2015-01-18, 1393/10/28**  
Registration timing: **retrospective**

Last update:  
Update count: **0**

##### Registration date

2015-01-18, 1393/10/28

##### Registrant information

###### Name

Gholamreza Askari

###### Name of organization / entity

Isfahan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 31 1792 2110

###### Email address

askari@mui.ac.ir

#### Recruitment status

##### Recruitment complete

##### Funding source

Isfahan University School of Nutrition

##### Expected recruitment start date

2014-10-23, 1393/08/01

##### Expected recruitment end date

2014-12-06, 1393/09/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of curcumin on liver function enzymes in patients with NAFLD

##### Public title

The effect of curcumin in the treatment of NAFLD

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: not suffering from diseases such as cardiovascular problems; kidney; lung; thyroid disorders and liver problems such as hepatitis; chronic liver disease; nonalcoholic fatty liver disease; Pregnant and milking ; BMW over 25; non-smoking and drugs such as celecoxib on inflammation. Exclusion criteria: patients with diseases such as cardiovascular problems; kidney; lung; thyroid disorders and liver problems such as hepatitis; chronic liver disease; nonalcoholic fatty liver disease; Become pregnant; smoking and drugs such as celecoxib on inflammation.

##### Age

From **76 years** old

##### Gender

Both

##### Phase

N/A

#### Groups that have been masked

No information

### Sample size

Target sample size: 80

### Randomization (investigator's opinion)

Randomized

### Randomization description

### Blinding (investigator's opinion)

Double blinded

### Blinding description

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

University of Medical Sciences

##### Street address

St. thousand acres, Isfahan University of Medical Sciences and Health Services, Headquarters

##### City

isfahan

##### Postal code

۷۳۴۶۱-۸۱۷۴۶

#### Approval date

2014-10-16, 1393/07/24

#### Ethics committee reference number

393581

## Health conditions studied

### 1

#### Description of health condition studied

nonalcoholic fatty liver

#### ICD-10 code

76.0

#### ICD-10 code description

Fatty (change of) liver, not elsewhere classified

## Primary outcomes

### 1

#### Description

ALT

#### Timepoint

Before and after study

#### Method of measurement

Enzymatic photometric

### 2

#### Description

AST

#### Timepoint

Before and after study

#### Method of measurement

Enzymatic photometric

## Secondary outcomes

### 1

#### Description

TG

#### Timepoint

Before and after study

#### Method of measurement

Enzymatic

### 2

#### Description

Tch

#### Timepoint

Before and after study

#### Method of measurement

Enzymatic

### 3

#### Description

HDL

#### Timepoint

Before and after study

#### Method of measurement

Enzymatic

### 4

#### Description

LDL

#### Timepoint

Before and after study

#### Method of measurement

Fried Wald Equation equation

### 5

#### Description

hs-CRP

#### Timepoint

Before and after study

#### Method of measurement

Aymynvasy sensitive enzymatic

### 6

#### Description

F.B.S

#### Timepoint

Before and after study

#### Method of measurement

Enzymatic

## 7

### Description

HBA1C

### Timepoint

Before and after study

### Method of measurement

Enzymatic

## Intervention groups

### 1

#### Description

Intervention: curcumin, Capsules, 500 mg orally, once daily for 2 months

#### Category

Placebo

### 2

#### Description

Control: placebo (bass calcium phosphate) Capsules 500 mg orally, once daily for 2 months

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Endocrinology and Metabolism Research Center, S. T.

##### Full name of responsible person

GholamReza Asgari doctor

##### Street address

Near the center of Smdyh Tee of St. Khurram S T (S)

##### City

Isfahan

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Isfahan University of Medical Sciences

##### Full name of responsible person

GholamReza Asgari doctor

##### Street address

Street thousand acres, Isfahan University of Medical Sciences and Health Services, Headquarters

##### City

Isfahan

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Isfahan University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

empty

#### Domestic or foreign origin

empty

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

empty

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Isfahan University of Medical Sciences

#### Full name of responsible person

GholamReza Asgari doctor

#### Position

PhD

#### Other areas of specialty/work

#### Street address

Street thousand acres, Isfahan University of Medical Sciences and Health Services, Headquarters

#### City

Isfahan

#### Postal code

۷۳۴۶۱-۸۱۷۴۶

#### Phone

+98 31 3668 0048

#### Fax

#### Email

askari@mui.ac.ir

#### Web page address

www.mui.ac.ir

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Isfahan University of Medical Sciences

#### Full name of responsible person

Gholamreza askari

#### Position

PhD

#### Other areas of specialty/work

#### Street address

Street thousand acres, Isfahan University of Medical Sciences and Health Services, Headquarters

#### City

Isfahan

#### Postal code

۷۳۴۶۱-۸۱۷۴۶

#### Phone

+98 31 3668 0048

#### Fax

#### Email

askari@mui.ac.ir

**Web page address**

www.mui.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Isfahan University of Medical Sciences

**Full name of responsible person**

Gholamreza askari

**Position**

phd

**Other areas of specialty/work****Street address**

Street thousand acres, Isfahan University of Medical Sciences and Health Services, Headquarters

**City**

Isfahan

**Postal code**

۷۳۴۶۱-۸۱۷۴۶

**Phone**

+98 31 3668 0048

**Fax****Email**

askari@mui.ac.ir

**Web page address**

www.mui.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*